KR20240055021A - Tead 저해제에 대한 투여 요법 - Google Patents

Tead 저해제에 대한 투여 요법 Download PDF

Info

Publication number
KR20240055021A
KR20240055021A KR1020247009905A KR20247009905A KR20240055021A KR 20240055021 A KR20240055021 A KR 20240055021A KR 1020247009905 A KR1020247009905 A KR 1020247009905A KR 20247009905 A KR20247009905 A KR 20247009905A KR 20240055021 A KR20240055021 A KR 20240055021A
Authority
KR
South Korea
Prior art keywords
cancer
tead
pharmaceutically acceptable
treatment
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247009905A
Other languages
English (en)
Korean (ko)
Inventor
에밀 하페아우
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20240055021A publication Critical patent/KR20240055021A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247009905A 2021-09-01 2022-08-30 Tead 저해제에 대한 투여 요법 Pending KR20240055021A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163239506P 2021-09-01 2021-09-01
US63/239,506 2021-09-01
PCT/IB2022/058130 WO2023031798A1 (en) 2021-09-01 2022-08-30 Dosing regimen for a tead inhibitor

Publications (1)

Publication Number Publication Date
KR20240055021A true KR20240055021A (ko) 2024-04-26

Family

ID=83355146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009905A Pending KR20240055021A (ko) 2021-09-01 2022-08-30 Tead 저해제에 대한 투여 요법

Country Status (11)

Country Link
US (1) US20240358720A1 (https=)
EP (1) EP4395768A1 (https=)
JP (1) JP2024532325A (https=)
KR (1) KR20240055021A (https=)
CN (1) CN117835977A (https=)
AU (1) AU2022340987A1 (https=)
CA (1) CA3225444A1 (https=)
IL (1) IL309246A (https=)
MX (1) MX2024002566A (https=)
TW (1) TW202327579A (https=)
WO (1) WO2023031798A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156404A1 (en) * 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4030233B1 (en) 2019-09-18 2025-05-07 Ningbo Sunny Opotech Co., Ltd. Periscopic camera module and electronic device
UY39129A (es) 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CA3205726A1 (en) 2021-01-25 2022-07-28 Alfredo C. Castro Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer

Also Published As

Publication number Publication date
IL309246A (en) 2024-02-01
US20240358720A1 (en) 2024-10-31
MX2024002566A (es) 2024-03-20
EP4395768A1 (en) 2024-07-10
JP2024532325A (ja) 2024-09-05
WO2023031798A1 (en) 2023-03-09
CN117835977A (zh) 2024-04-05
AU2022340987A1 (en) 2024-01-18
CA3225444A1 (en) 2023-03-09
TW202327579A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
AU2013203637B2 (en) Combination therapy for proliferative disorders
JP2017519019A (ja) ｍｄｍ２阻害剤の間欠投与
IL224395A (en) Two-component pharmacist product for use in treating cancer with b-raf mutant v600
EA029072B1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
KR20250013187A (ko) 니로가세스타트를 사용한 치료
AU2019263026B2 (en) Combinations for treating cancer
KR20240055021A (ko) Tead 저해제에 대한 투여 요법
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
JP2025503066A (ja) 腫瘍を治療するための医薬組み合わせ及び使用
US20230038138A1 (en) Combination therapy for treating cancer
CN110494137B (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
EP4504180A1 (en) Combination therapy for treating cancer
EP4504182A1 (en) Combination therapy for treating cancer
WO2025229127A1 (en) A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
KR20240044419A (ko) Erk1/2 및 egfr 억제제 조합 요법
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
CA3198190A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
HK40041700A (en) Combinations for treating cancer
JP2009108058A (ja) 抗リンパ腫組成物および方法
EA039396B1 (ru) Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D12 Request for substantive examination rejected

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D12-EXM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000